CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma: Grade ≥3 and serious TEAEs, respectively, were more frequent in the DLBCL (70.6% and 58.8%) and PTCL (81.8% and 63.6%) cohorts than in the cHL cohorts (5.6% and 11.1% [cHL anti‐PD‐1/PD‐L1 naïve], 8.3% and 16.7% [cHL anti‐PD‐1/PD‐L1 progressors]).